Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SRC | P12931 | 11/20 | 0.57 |
| ▸ | FYN | P06241 | 1/20 | 0.53 |
| ▸ | ABL1 | P00519 | 2/20 | 0.53 |
| ▸ | BCR | P11274 | 2/20 | 0.53 |
| ▸ | EGFR | P00533 | 1/20 | 0.53 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.53 |
| ▸ | MAP2K1 | Q02750 | 8/20 | 0.51 |
| ▸ | MAPK3 | P27361 | 2/20 | 0.49 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.49 |
| ▸ | IGF1R | P08069 | 1/20 | 0.49 |
| ▸ | MAP3K1 | Q13233 | 1/20 | 0.49 |
| ▸ | RAF1 | P04049 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4664563 | 0.90 | EHMT2 (0.52) | SRCFYNABL1BCREGFR | |
| SCHEMBL4664106 | 0.88 | WEE2 (0.54) | SRCFYNABL1BCREGFR | |
| SCHEMBL4664567 | 0.86 | SRC (0.45) | SRCFYNABL1BCREGFR | |
| SCHEMBL903068 | 0.83 | EGFR (0.64) | SRCABL1EGFRERBB2 | |
| SCHEMBL5097860 | 0.83 | EGFR (0.64) | SRCABL1EGFRERBB2 | |
| SCHEMBL14667307 | 0.82 | EGFR (0.47) | SRCABL1EGFRERBB2 | |
| Hydrochloric Acid SCHEMBL6432089 | 0.82 | EGFR (0.62) | SRCABL1EGFRERBB2 | |
| SCHEMBL6431782 | 0.81 | SRC (0.60) | SRCFYNABL1BCREGFR | |
| SCHEMBL4667696 | 0.79 | TBK1 (0.39) | SRC | |
| SCHEMBL14540831 | 0.78 | AXL (0.56) | SRCFYNABL1BCREGFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6977259-B2 | Quinoline derivatives and their use as aurora 2 kinase inhibitors | ASTRAZENECA AB (SE) | 2005-12-20 | — | — | US | disclosed |
| US-20030105129-A1 | Chemical compounds | ASTRAZENECA AB (SE) | 2003-06-05 | — | — | US | disclosed |
| EP-1294709-A2 | QUINOLINE DERIVATIVES AND THEIR USE AS AURORA 2 KINASE INHIBITORS | AstraZeneca AB (SE) | 2003-03-26 | — | — | EP | disclosed |
| WO-2001055116-A2 | QUINOLINE DERIVATIVES AND THEIR USE AS AURORA 2 KINASE INHIBITORS | ASTRAZENECA AB (SE) | 2001-08-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030105129-A1 | Chemical compounds | AURKC, AURKA, AURKB | SRC 114/4885FYN 998/4885ABL1 429/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.